In Alzheimer’s disease, the most common dementia (50–70% of all clinical diagnoses), pathological tau load correlates closely with cognitive decline, suggesting that tau is a suitable biomarker for monitoring of disease progression [1, 14]. This evidence concerns the gene MAPT and Mental deterioration.